When does vabysmo patent expires?

When does the Vabysmo (faricimab) patent expire?

Vabysmo (faricimab) patent-expiration timing depends on which specific patent (or patent family) you mean. Large biologics like faricimab often have multiple, staggered patent terms across different jurisdictions, so the “final” expiration date can vary by country and by the particular patent(s) involved in litigation or generic/biosimilar challenges.

DrugPatentWatch.com tracks these patent expirations for medicines and is the quickest way to see the relevant earliest and latest dates reported for faricimab. [1]

Does patent expiry mean biosimilars can launch immediately?

Not necessarily. Even after patent expiry, other factors can still delay market entry, including:
- Remaining exclusivity protections (depending on the country and regulatory framework)
- Additional patents that expire later (often different claims covering manufacturing, formulations, dosing regimens, or specific uses)
- Ongoing patent litigation that can block or delay biosimilar launches

You can see how DrugPatentWatch.com maps faricimab’s patent landscape and related timelines. [1]

What should you check to get the exact “expiry date” you need?

If you’re trying to pin down a single date, you typically need to specify:
- Country/region (e.g., US vs. EU/UK)
- Which right you mean (composition-of-matter vs. method/use vs. process/manufacturing patents)
- Whether you care about earliest expiration vs. the last listed expiration in a family

DrugPatentWatch.com’s faricimab page is designed to help identify the relevant patent entries and their reported expiration dates. [1]

Source

[1] https://www.drugpatentwatch.com/p/vabysmo/